The epigenetic regulator TET2 is frequently mutated in hematological diseases. Mutations have been shown 2 to arise in hematopoietic stem cells early in disease development, lead to altered DNA methylation 3 landscapes and to an increased risk of hematopoietic malignancy. Here, we show by genome-wide mapping 4 of TET2 binding sites in different cell types that TET2 localizes to regions of open chromatin and cell-type 5 specific enhancers. We find that deletion of Tet2 in native hematopoiesis as well as fully transformed Acute 6 Myeloid Leukemia (AML) results in changes in transcription factor (TF) activity within these regions, and we 7 demonstrate that loss of TET2 leads to enzymatic activity-dependent attenuation of chromatin binding of the 8 hematopoietic TF CDX4. Together, these findings demonstrate that TET2 activity shapes the local chromatin 9 environment at enhancers to facilitate TF binding and provide a compelling example of how epigenetic 10 dysregulation can affect gene expression patterns and drive disease development.
INTRODUCTION 1
The Ten-Eleven-translocation (TET) enzymes (TET1-3) mediate active DNA demethylation of cytosines in CG 4 presence of a nucleosome-depleted region (Stadler et al. 2011; Thurman et al. 2012) . While much work has 1 focused on understanding the role of aberrant TF expression in leukemia, less is known about the role of the 2 chromatin environment, and hence DNA methylation (Blattler and Farnham 2013) , in modulating TF access 3 to their cognate binding sites.
4
The occurrence of enhancer DNA hypermethylation and hematological malignancies upon TET2 5 mutation challenges a widely held view that DNA methylation does not pose a challenge for TF binding 6 (Thurman et al. 2012) . Although several TFs have been demonstrated to bind methylated DNA and induce 7 DNA hypomethylation (e.g. CTCF and REST) (Lienert et al. 2011; Stadler et al. 2011 ), many TFs show an 8 inherent binding preference in vitro for motifs with either methylated or unmethylated CpG sites (Yin et al. 9 2017). As an illustration of this, global loss of DNA methylation in embryonic stem (ES) cells was shown to 10 unmask previously inaccessible genomic binding sites for the TF NRF1 (Domcke et al. 2015) . Moreover, DNA 11 methylation and TET-mediated oxidation products potentially influence binding of epigenetic "readers" (e.g.
12
Methyl-Binding Domain (MBD) proteins) (Song and Pfeifer 2016), histone variants and nucleosome 13 remodeling enzymes (Conerly et al. 2010; Brunelle et al. 2015) , and modify the physical properties of 14 chromatin and DNA itself (Ngo et al. 2016) . Thus, the dynamics of DNA methylation and TET-mediated 15 cytosine oxidation at gene-regulatory elements may, under certain circumstances, modulate their function.
16
Despite advances in the identification of epigenetic changes in TET2 mutated cells, the mechanisms 17 by which aberrant DNA methylation promotes hematopoietic stem cell expansion and malignancy remain 18 poorly understood. Here, we use genomic profiling to dissect the functional consequences of TET2 ablation 19 in ES cells and in vivo models of CH/CCUS and AML. We find that TET2 binding and catalytic activity at 20 enhancers facilitate recruitment of key hematopoietic TFs and we propose that this, mediates at least some 21 of the phenotypic effects of TET2 mutations in hematopoiesis. (Ko et al. 2010; Asmar et al. 2013; Hon et al. 2014; Rasmussen et al. 2015; Yamazaki et al. 2015) .
27
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5
However, it still remains unclear which regions are directly targeted by TET2 as opposed to being secondary 1 effects of its depletion. To address this, we developed and optimized reagents and protocols for genome-2 wide mapping of TET2 occupancy using chromatin immunoprecipitation (ChIP) in wildtype and epitope-3 tagged cell lines (see Supplemental methods and Fig. S1 for full detail).
4
We first determined the genomic binding regions of TET2 in ES cells using antibodies to TET2 (TET2-5 N) or to an epitope-tagged TET2 expressed from the endogenous Tet2 locus (FLAG M2). TET2 binding sites 6 were defined by enrichment over non-specific ChIP enriched regions identified in Tet2 knockout cells or 7 Rasmussen et al.
6
parental cells without FLAG-tagged TET2. In total, this analysis revealed 26,512 TET2-bound regions of which 1 approximately one-third, referred to as "high-confidence" TET2 binding sites, were identified with both 2 antibodies and had a stronger ChIP-seq signal ( Fig 1A) . Strikingly, the vast majority (93.4%) of these 8,262
3 sites were localized in regions of open chromatin defined by DNaseI hypersensitivity (DHS) ( Fig. 1B and 1C ).
4
To understand whether TET2 is enriched in specific regions of open chromatin in the genome, we 5 compared high-confidence TET2 binding sites to sets of random control regions (x5) matched for size, 6 orientation, and distance to DHS sites. This showed a strong enrichment of TET2 high-confidence binding 7 sites at DHS with enhancer features such as p300 binding (4-fold), H3K27ac (2.5-fold), and H3K4me1 (1.6-8 fold), whereas TET2 binding at promoters, CpG islands, and CTCF binding sites was depleted (~0.3-fold each) 9 ( Fig 1D) . This binding pattern is illustrated by a representative TET2-bound enhancer region 10kb upstream 10 of the master ES regulator Zfp281 (Fig. 1E ). Notably, up to 90% of TET2 high confidence binding regions are 11 associated with features of distal regulatory elements (p300, H3K27ac, H3K4me1, or DHS) and nearly half of 12 TET2-bound regions overlap with promoter-distal p300 binding sites ( Fig 1F) . Chromatin occupancy of p300 13 is a hallmark of active enhancers and a biochemical interaction between p300 and TET2 has recently been 14 reported (Heintzman et al. 2007; Zhang et al. 2017) . Thus, our data are in agreement with a model in which 15 TET2 can be directly recruited to a subset of its chromatin targets via a direct interaction with p300 (Zhang 
17
A previous study has examined the genome-wide changes in 5-methylcytosine (5mC) and 5-18 hydroxymethylcytosine (5hmC) that occur upon Tet2 knockout in ES cells (Hon et al. 2014) . We used this 19 dataset to identify epigenetic changes around (+/-250bp) high-confidence TET2 binding sites. Genetic 20 knockout of Tet2 is likely to result in gain of 5mC (due to absence of DNA demethylation), loss of 5hmC (stable 21 product of methylcytosine oxidation by TET2), or both, at sites of TET2 recruitment. Importantly, we found 22 such changes (hyper-5mC, hypo-5hmC, or both) at the majority of high-confidence TET2 binding sites (~93%) 23 ( Fig. 1G ) thereby confirming that TET2 modifies the DNA methylation state. The analysis was repeated with 24 the full set of 26,512 sites with evidence of TET2 binding (Fig. S2A ). Within this larger and less stringent set 25 of regions, we observed a modest enrichment of TET2 binding at CpG islands and gene promoters ( Fig. S2B ).
26
However, in contrast to a pronounced DNA hypermethylation at sites co-bound by TET2 and p300, DNA 7 methylation did not change at these CpG islands and promoters in Tet2-deficient ES cells ( Fig S2C and S2D ).
1 This is consistent with the previously identified role of TET2 in maintaining a low level of DNA methylation at 2 distal regulatory elements, whereas CpG islands and promoters are protected from DNA hypermethylation 3 by additional mechanisms (Rasmussen and Helin 2016) . It should be noted that most differentially 4 methylated regions reported in Tet2 knockout ES cells (over 60,000 hyper-DMRs and 130,000 hypo-DMRs) 5 did not show detectable binding of TET2 in our dataset (Fig. S2E ). This suggests either that TET2 functions in 6 the absence of robust and persistent binding at these sites or that some of these methylation changes 7 (especially hypo-DMRs) can occur as a consequence of secondary events to TET2 depletion. Taken together, between ES cells and myeloid cells ( Fig. 2A ).
17
We then overlapped the TET2 myeloid binding sites with various genomic regions. Although binding 18 of TET2 could be detected in a subset of promoters and CpG islands, the majority of binding sites was 19 promoter-distal (67.4%) and nearly half (44.4%) associated with enhancer features (Fig. 2B ). An illustrative 20 example of this binding pattern is shown at enhancers upstream of the hematopoietic master regulator 21 Gata2 (Fig. 2C ). Since promoter DNA methylation patterns are largely unaffected by depletion of TET2, we 22 decided to focus our analysis on promoter-distal TET2 binding sites. Identification of enriched gene ontology 23 (GO) terms by genomic regions enrichment of annotations tool (GREAT) revealed a striking separation by cell 24 type. For example, the GO terms "stem cell maintenance" and "blastocyst formation" were enriched for TET2 25 binding sites in ES cells, whereas "immune system process" was highly significant for sites in myeloid cells 26 ( Fig. S2F and S2G ). Next, we performed motif enrichment analysis of known DNA-binding TFs. The top 8 enriched motifs belonged to master TFs of the respective cell types such as SOX2, KLF4, ESRRG, OCT4 and 1 NANOG in ES cells and e.g. ERG, RUNX1, CEBPA, GATA1 in myeloid cells ( Fig. 2D and 2E ). Together, these 2 results indicate that TET2 is recruited to chromatin in a highly cell-type specific manner and that TET2 binding 3 at promoter-distal regulatory elements co-localizes with a wide range of predicted TF binding sites. To recapitulate this in a mouse model, we induced hematopoietic-specific Tet2 deletion in young 11 adult mice and allowed them to age to 10 months (40 weeks). Aged Tet2-deficient mice had increased levels 12 of Lin -Sca + cKit + (LSK) cells in the bone marrow and spleen, mild splenomegaly, and a mild anemia in the 9 peripheral blood ( Fig S3A-S3D) . Thus, this mouse model approximates hematopoietic features observed in 1 aged individuals with CH/CCUS and allows for molecular profiling of hematopoietic stem cells in their native 2 microenvironment.
3
It has been demonstrated that native hematopoiesis is predominantly sustained by multipotent 4 progenitors (MPP) throughout the lifetime of the mouse (Sun et al. 2014; Busch et al. 2015) . We therefore 5 decided to perform genomic profiling on wildtype and Tet2-deficient MPPs as well as downstream myeloid-6 lineage progenitors (Granulocyte-Monocyte Progenitors, GMP) ( Fig 3A and S3E) . Analysis of differentially 7 regulated genes in TET2 depleted cells revealed relatively few expression changes in MPPs (106 genes, q-8 value < 0.1), whereas GMPs had 8-fold higher number of up-and down-regulated genes ( Fig S3F and Table   9   S1 ). Yet, comparison of differentially expressed genes identified several important regulators of 10 hematopoiesis to be aberrantly expressed in both cell types (e.g. Up: Zbtb16, Runx1, Pdgfrb, down: Etv5, 11 Gfi1) (Fig. 3B) . Interestingly, gene set enrichment analysis (GSEA) revealed a general downregulation in Tet2-12 deficient MPPs of gene signatures of translation, ribosome biogenesis and metabolism (Fig. 3C, S3G and Table   13 S2). This is consistent with a report identifying lower metabolic rate and reduced ribosome biogenesis as 10 hallmarks of preleukemic stem cells (Cai et al. 2015) . Indeed, the total content of RNA, most of which is 1 comprised of ribosomal RNA, was decreased in sorted Tet2-deficient MPPs (Fig. 3D ). depleted condition and vice versa. Thus "TF activity" is here defined as the TF being associated with increased 25 chromatin accessibility at its target sites. 1 ( Fig. 4A and Fig. S4 ). In GMP cells, we could detect a signature of aberrant lineage differentiation 2 characterized by increased activity of the IRF family of TFs (IRF8, IRF1 and IRF2) and decreased activity of 3 TAL1 and the GATA family members (GATA1, -2 and -3). Conversely, MPP cells showed a significant increase 4 in chromatin accessibility in predicted binding sites of the CCAAT/Enhancer binding protein family (C/EBP-5 alpha, -beta, -gamma, -delta, HLF) as well as CCCTC-binding factor (CTCF) protein. Interestingly, previous 6 studies have suggested that C/EBP-beta has a slight preference for binding to motifs with a methylated 7 cytosine (Mann et al. 2013; Zhu et al. 2016) , thus potentially implicating TET2 as a factor that restricts C/EBP-8 beta binding to chromatin. In the other extreme, we observed a significant decrease in the activity of several 9 TFs including homeodomain TFs CDX4, EVX1 and HOXC6, as well as the E proteins: E2-2 and ZEB1.
12
To validate the biological significance of these changes in hematopoietic differentiation we focused 1 on E2-2, whose activity showed a decrease upon Tet2 knockout in both MPPs and GMPs (Fig. 4A and Fig. S4 ).
2
E2-2 is a well-studied hematopoietic TF (reviewed in (Kee 2009)), and is a member of the basic Helix-Loop-3 Helix (bHLH) TF family whose in vitro DNA binding is inhibited by DNA methylation (Yin et al. 2017) . In contrast 4 to the loss of TF activity, we found that the mRNA levels of E2-2 as well as the closely related E proteins E2A, 5 HEB and ZEB1 (Fig. 4B) were unchanged in Tet2-deficient MPPs (Fig. 4C) . Mice with hematopoietic-specific 6 knockout of one allele of E2-2 display defects in differentiation of plasmacytoid dendritic cells (pDCs) and low 7 expression of key pDC-associated genes (Cisse et al. 2008) . We reasoned that a change in E2-2 activity should 8 recapitulate these effects of reduced E2-2 expression. Consistent with this, we observed decreased 9 expression of the target genes Ccr9 and Dntt in Tet2 knockout MPPs (Fig. 4C ) and a partial impairment of pDC 10 development in Tet2-deficient animals (Fig 4D and 4E ).
11
Overall, these results suggest that the knockout of Tet2 phenocopies the haploinsufficiency of E2-2 12 in hematopoietic stem cells by decreasing the binding activity of E2-2 rather than changing its expression. colony-forming capacity and accelerated the onset of disease ( Fig. S5B and S5C ). Furthermore, primary 13 leukemic cells from moribund mice can be maintained and expanded in vitro and these cells maintain 1 leukemogenicity even after extensive cell culture passaging (Fig S5D and S5E) . Characterization of surface 2 marker expression in the bulk in vitro culture revealed sustained proliferation of CD34 + CD16/32 int CD11b -Gr1 -3 cells, whereas more differentiated cells in the clonal hierarchy did not grow (Fig. S5F) . Thus, we purified this 4 leukemogenic precursor population (CD34 + CD16/32 int CD11b -Gr1 -) from wildtype and Tet2-knockout cultures 5 for analysis of chromatin accessibility by ATAC-seq. 6 diffTF analysis of AML cells with Tet2 knockout versus wildtype identified decreased TF activity of 7 members of the HoxB gene cluster including HOXB7 and HOXB8 as well as the TFs MITF and STAT6 (Fig. 5A ).
1 Importantly, the decrease of CDX4/EVX1 activity upon loss of TET2 was observed in both MPP cells and AML 2 cells suggesting that TET2 supports TF binding at these sites in both normal and malignant hematopoiesis 3 ( Fig. 5A) . Due to the similarity of their reported DNA binding motif, the effects of CDX4 and EVX1 are difficult 4 to distinguish based on binding site predictions (Fig. 5B ). To disentangle their effects, we performed 5 quantitative RT-PCR and found similar expression levels of CDX4 mRNA in wildtype and Tet2 deleted LSK cells, 6 whereas expression of EVX1 was not detectable in either (Fig. 5C ). In addition, we observed similar levels of 7 CDX4 protein expression in wildtype and Tet2-null AML and ES cells ( Fig. 5D and 5E ). Finally, a role for CDX4 8 has been described in early hematopoietic development in the embryo as well as adult hematopoiesis (Bansal 9 et al. 2006; Wang et al. 2008; Koo et al. 2010; Rawat et al. 2012; McKinney-Freeman et al. 2008 ), whereas
10
EVX1 has yet to be implicated in these processes. Hence, we conclude that the reduced accessibility at 11 predicted CDX4/EVX1 sites in hematopoietic cells most likely stems from loss of CDX4 binding upon loss of 12 TET2. Reduction of CDX4 activity furthermore occurs predominantly at promoter-distal regions (Fig. S4A see   13 "AML.ProDistal") and is observed at sites of TET2 binding in AML cells ( Fig. S4A see "AML.ChIP"). To assess 14 the functional role of the altered TF activity, we analyzed the relationship between TF activity differences 15 reported by diffTF and the differential expression pattern of predicted target genes in proximity to the TF 16 binding sites using RNA-seq data from MPPs. Importantly, we observed an overall decrease of CDX4/EVX1 17 target gene expression thus confirming the role of CDX4 as an activator of gene expression ( Fig. S6E ).
18
To investigate whether chromatin recruitment of CDX4 is promoted by catalytic activity-dependent 19 or -independent functions of TET2, we transduced AML cells with lentiviruses (LVs) expressing wildtype and 20 a catalytic dead (HxD) version of the TET2 catalytic domain (Fig. 5F ). We then quantified chromatin 21 accessibility in predicted CDX4 binding sites by ATAC-seq. Despite higher expression of TET2-HxD compared 22 to TET2-WT in the Tet2 knockout cells (Fig. 5G) , only TET2-WT was able to partially rescue CDX4 binding as 23 indicated by increased chromatin accessibility at a subset of predicted binding sites (left tail) (Fig. 5H ). This 24 was furthermore confirmed by an overall increase in chromatin accessibility in cells expressing TET2-WT 25 compared to cells expressing TET2-HxD (Mann-Whitney non-parametric, P = 0.0024) (Fig. 5H) . Thus, we 26 conclude that the catalytic activity of TET2 is necessary to sustain chromatin accessibility at a subset of 1 chromatin environment to support CDX4 chromatin binding. The lack of ChIP-grade antibodies for CDX4 makes it difficult to directly assess its chromatin occupancy in 5 hematopoietic cells. This prompted us to investigate Tet2-dependent CDX4 chromatin binding in ES cells, a 6 cell type with a well-described role for CDX4 in promoting hematopoietic differentiation (Wang et al. 2008;  7 McKinney-Freeman et al. 2008) . We engineered a mouse ES cell line on a Tet2 fl/fl ; Rosa26-Cre +/ERT2 genetic 8 background with stable expression of murine CDX4 with two copies of the FLAG tag (2xFL). This enables analysis of CDX4 chromatin occupancy before and after inducible deletion of Tet2 by addition of 4-1 hydroxytamoxifen (4-OHT) (Fig. 6A ). ChIP-seq analysis identified a total of 13,977 enriched regions in 2xFL-2 CDX4 expressing cells compared to the parental cells without 2xFL-CDX4 expression ( Fig. 6B) . As a quality 3 control, we analysed DNA sequences at CDX4 enriched regions by TF DNA-binding motif enrichment analysis.
4
The top enriched motif (E-value = 1.1e-529) was highly similar to the DNA binding motif of the ParaHox class 5 of TFs (Cdx1, Cdx2, and Cdx4), thus providing an independent validation of the ChIP results (Fig. S6F ).
6
Next, we evaluated the ChIP signal within CDX4 peaks after Tet2 deletion. Although the effect on 7 CDX4 binding sites was highly locus-specific, we found an overall loss of CDX4 chromatin occupancy upon 8 Tet2 knockout, and quantification revealed a decrease in normalized read counts at a majority of CDX4-bound 9 regions (~83%) (Fig. 6B ). An illustrative example of loss of CDX4 binding is shown for an enhancer region co-10 bound by CDX4, TET2 and p300 in ES cells (Fig. 6C) . To test for a direct effect of TET2, we selected the top 11 and bottom 500 regions with the strongest loss and gain of CDX4 binding, respectively (Fig. 6D) , and 12 overlapped these with TET2 binding sites in ES cells. Importantly, we found a significantly higher overlap of 13 TET2-positive regions (Fig. 6E) as well as normalized read counts (Fig. 6F) 
17
6G). Together with the diffTF analysis, these results provide strong evidence that CDX4 chromatin occupancy 18 is adversely affected by Tet2 knockout likely through an increase in DNA methylation at CDX4 binding sites.
20

DISCUSSION
21
While DNA methylation landscapes in TET2-mutated cells have been extensively characterized (Ko et al. 2010;  22 Asmar et al. 2013; Hon et al. 2014; Rasmussen et al. 2015; Yamazaki et al. 2015) , much less is known about 23 the functional consequences that ultimately drive hematopoietic stem cell expansion and malignancy. Here,
24
we resolve the inconsistency between regions reported to be bound by TET2 (Chen et al. 2013; Deplus et al. 25 2013; Peng et al. 2016 ) and those affected by TET2 catalytic function. We show that TET2 is predominantly 26 recruited to promoter-distal regions of open chromatin, including enhancers. Therefore, it is likely that it is epigenetic perturbation of these elements that results in dysregulated hematopoiesis of TET2-mutated stem 1 cells, possibly through pleiotropic effects on many genes that together derail homeostasis and 2 differentiation. Interestingly, a recent study has reported a direct biochemical interaction between the 3 histone acetyltransferase p300 and TET2 (Zhang et al. 2017) . In ES cells, we find that approximately half of 4 high-confidence TET2 binding sites co-localize with p300-enriched regions (Fig. 1A) and nearly half of all p300-5 enriched regions show evidence of TET2 binding (Fig. S2B) . Taken together these results may suggest that 6 p300 is involved in recruiting TET2 to chromatin through direct protein-protein interactions. However, a 7 direct validation of this, as well as a comprehensive analysis of the role of additional potential recruiters, 8 such as WT1 (Rampal et al. 2014; Wang et al. 2015) , remain an area of active investigation.
9
To dissect the impact of TET2 loss in hematopoiesis, we investigated genome-wide changes in 10 enhancer function using chromatin accessibility as a measure of activity in a native chromatin context. We (Fig. S4A ). It should be noted that additional TF binding events that 18 were not identified in this study may also require TET2 activity; however, such TFs may not show strong 19 global differences or are not detected from analysis of chromatin accessibility alone (e.g. because they lack 20 a known binding motif).
21
We found decreased activity of the regulator of hematopoietic development, CDX4 (Bansal et al. 
24
this suggests that TET2 promotes CDX4 chromatin binding, and hence CDX4-driven gene expression. In 25 support of this, we could detect a decreased expression of CDX4/EVX1 target genes in MPP cells upon 26 ablation of TET2 (Fig. S6E ). In addition, we show that the catalytic activity of TET2 is required for CDX4 TF activity and demonstrate that loss of CDX4 chromatin binding in TET2-null ES cells coincides with increased 1 DNA methylation. It should be noted that the functional outcome of a DNA hypermethylation event caused 2 by impaired TET2 function is likely to be strongly influenced by locus-specific factors such as CpG density and 3 positioning, chromosomal conformation, properties of bound chromatin factors as well as redundant and/or 4 combinatorial enhancer function. Accordingly, only a small fraction of predicted CDX4 binding sites (~2.5%) 5 contained a CG dinucleotide in their motif. This suggests that it is aggregate remodeling of the chromatin 6 environment in and around the binding site, and not only direct DNA methylation at the motif, that disfavors 7 CDX4 binding. Thus, our results support a model by which TET2 recruitment and catalytic functions are 8 necessary to shape the chromatin structure for permissive TF binding at a majority of CDX4-bound enhancers 9 in hematopoietic cells. The precise molecular events that culminate in loss of CDX4 binding at these sites 10 remain to be determined.
11
Frequent mutations in the DNA methylation machinery have been found in patients suffering from 12 hematological diseases as well as solid cancers (Rasmussen and Helin 2016). Yet, whether DNA methylation 13 is causally involved in shaping gene expression patterns, rather than passively mirroring transcriptional 14 states, is still a matter of debate (Schübeler 2015) . Here, we present data in support of a role of TET2- 
